Pulmatrix has initiated a Phase 1B study of its PUR0200, an inhaled LAMA for the treatment of COPD, the company says. PUR0200 is a lactose-free formulation created using the company’s iSPERSE particle engineering technology.
Pulmatrix Chief Scientific Officer David Hava said, “PUR0200 has demonstrated outstanding performance in preclinical evaluation models of airway bronchoconstriction. The engineered aerosol performance and delivery characteristics of the iSPERSE platform are expected to result in PUR0200 efficacy at low doses. We look forward to the results in 2014.”
CEO Robert Clarke added, “This trial with PUR0200 is a very exciting step for Pulmatrix as it marks the first clinical study of a drug formulation based on our iSPERSE technology. We are hopeful that PUR0200 will be the first step in the establishment of a new generation of easily inhaled, easy-to-use therapeutics based on the iSPERSE technology to serve COPD, asthma, Cystic Fibrosis, and other patients suffering from respiratory disease.”
Quotient Clinical is manufacturing the product and conducting the clinical trial .
Read the Pulmatrix press release.
